



The IBAM CLL is a biennial meeting that was created by the interest that regional CLL and other related lymphoproliferative disorders awaken in regional basic and clinical researchers, both in terms of biology and therapeutic treatments. The Founding Presidents belong to three countries in our region: Uruguay, Brazil and Argentina. In charge of Prof. Guillermo Dighiero, the first IBAM CLL was held in Punta del Este, Uruguay, 15-17 November, 2013. The second IBAM CLL was held in São Paulo, Brazil, 23-24 September, 2016 and was chaired by Carlos Sérgio Chiattonne.

As previous meetings, the main goal of the next 3rd IBAM CLL 2018 is to promote the exchange of information and to foster collaboration between international leaders and regional clinicians and scientists interested in CLL and lymphoproliferative disorders.

PROGRAM

Master Lecture 1:

Daniel Catovsky Overview on familial CLL.

Master Lecture 2:

Guillermo Dighiero Unsolved issues in CLL biology and prognosis.

Lecture 1:

Thomas Kipps Tumoral microenvironment in CLL.

Lecture 2:

Nicholas Chiorazzi Dueling selections for and against auto and foreign antigens in the evolution of CLL stereotyped subset #4.

Lecture 3:

Jacqueline Barrientos Monoclonal antibodies in CLL.

Lecture 4 :

Nicholas Chiorazzi The origin of CLL-B cell.

Lecture 5:

Michael Hallek Treatment for relapsed C.

Iberoamerican Symposium:

Francesc Bosch The clinica implications of gene mutations in CLL.

Rocío Hassan TP53 mutations.

Pablo Oppezzo Unraveling the mutatioal landscape in progressive CLL patients.

Research in Latin America

Session 1:

Selected abstract 1: Chronic lymphocytic leukemia cells from progressive patients inhibit infammasome and avoid pyroptosis cell death.

- Selected abstract 2: Autologous T cell activation fosters venetoclax resistance in CLL: rationale for a combined therapy with the BCR kinase inhibitor GS-9973 and anti-CD20 mAbs.
- Session 2:
- Selected abstract 3: Metabolomics approach in chronic lymphocytic leukemia.
- Selected abstract 4: Development of artificial binding proteins for specific ROR1-binding and tumor targeting.
- Session 3:
- Selected abstract 5: Prognostic molecular biomarkers in chronic lymphocytic leukemia (CLL), a cohort of argentinian patients.
- Selected abstract 6: Results of mutational status of immunoglobulin heavy-chain variable gene analysis in a cohort of patients with B-CLL. A single centre experience.
- Selected abstract 7: A paucity of VH3-21 and a distinct pattern of stereotyped B-cell receptors in chronic lymphocytic leukemia from Brazil.
- Session 4:
- Selected abstract 8: Estudio de sobreexpresión de AID y LPL vinculado al índice CLL-IPI y su impacto sobre el tiempo de inicio de tratamiento.
- Selected abstract 9: AID-related somatic signatures and their role in tumor progression of class switched vs non-switched B-CELL neoplasms.
- Session 5:
- Selected abstract 10: Association between micronucleus formation and genomic complexity in patients with chronic lymphocytic leukemia.
- Selected abstract 11: Chronic lymphocytic leukemia: protein kinase Akt and microRNAs gene expression evaluation and their importance in disease pathogenesis.
- Presentation:
- Marcio Nucci Infections in CLL.